Show simple item record

dc.contributor.authorKibirige, Davis
dc.contributor.authorAtuhe, David
dc.contributor.authorKampiire, Leaticia
dc.contributor.authorKiggundu, Ssekikubo Daniel
dc.date.accessioned2021-04-22T12:24:58Z
dc.date.available2021-04-22T12:24:58Z
dc.date.issued2017-08-24
dc.identifier.citationKibirige, D., Atuhe, D., Kampiire, L., Kiggundu, D.S., Donggo, P., Nabbaale, J., Mwebaze, R.M., Kalyesubula, R. and Lumu, W., 2017. Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study. International journal for equity in health, 16(1), pp.1-12.en_US
dc.identifier.issn1475-9276
dc.identifier.urihttp://hdl.handle.net/20.500.12280/2689
dc.description.abstractBackground: Despite the burgeoning burden of diabetes mellitus (DM) and cardiovascular diseases (CVD) in low and middle income countries (LMIC), access to affordable essential medicines and diagnostic tests for DM and CVD still remain a challenge in clinical practice. The Access to Cardiovascular diseases, Chronic Obstructive pulmonary disease, Diabetes mellitus and Asthma Drugs and diagnostics (ACCODAD) study aimed at providing contemporary information about the availability, cost and affordability of medicines and diagnostic tests integral in themanagement of DM and CVD in Uganda. Methods: The study assessed the availability, cost and affordability of 37 medicines and 19 diagnostic tests in 22 public hospitals, 23 private hospitals and 100 private pharmacies in Uganda. Availability expressed as a percentage, median cost of the available lowest priced generic medicine and the diagnostic tests and affordability in terms of the number of days’ wages it would cost the least paid public servant to pay for one month of treatment and the diagnostic tests were calculated. Results: The availability of the medicines and diagnostic tests in all the study sites ranged from 20.1% for unfractionated heparin (UFH) to 100% for oral hypoglycaemic agents (OHA) and from 6.8% for microalbuminuria to 100% for urinalysis respectively. The only affordable tests were blood glucose, urinalysis and serum ketone, urea, creatinine and uric acid. Parenteral benzathine penicillin, oral furosemide, glibenclamide, bendrofluazide, atenolol, cardiac aspirin, digoxin, metformin, captopril and nifedipine were the only affordable drugs. Conclusion: This study demonstrates that the majority of medicines and diagnostic tests essential in the management of DM and CVD are generally unavailable and unaffordable in Uganda. National strategies promoting improved access to affordable medicines and diagnostic tests and primary prevention measures of DM and CVD should be prioritised in Uganda.en_US
dc.language.isoenen_US
dc.publisherBMCen_US
dc.relation.ispartofseriesInternational journal for equity in health;16(1)
dc.subjectAvailabilityen_US
dc.subjectCosten_US
dc.subjectAffordabilityen_US
dc.subjectDiabetes mellitusen_US
dc.subjectCardiovascular diseasesen_US
dc.subjectLow and middle income countriesen_US
dc.titleAccess to Medicines and Miagnostic Tests Tntegral in the Management of Diabetes Mellitus and Cardiovascular Diseases in Ugandaen_US
dc.title.alternativeInsights From the ACCODAD Studyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record